Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,115.31
    +36.45 (+0.45%)
     

  • Bitcoin USD

    64,151.77
    +666.35 (+1.05%)
     

  • CMC Crypto 200

    1,389.45
    -7.09 (-0.51%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,360.70
    +18.20 (+0.78%)
     

  • Crude Oil

    84.13
    +0.56 (+0.67%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Will Conatus Pharmaceuticals (CNAT) Continue to Surge Higher?

Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Conatus Pharmaceuticals Inc (CNAT). The stock has moved higher by 27.2% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider CNAT’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as CNAT has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company.





CONATUS PHARMACEUTICALS INC (CNAT): Free Stock Analysis Report


Zacks Investment Research